← Leaderboards
Gary E Schiltz
Northwestern University
$5,645,620
Attributed
$12,258,974
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,258,974 · 7
By mechanism
R01$10,586,414 · 6
R56$1,672,560 · 1
Top collaborators
- Leonidas C Platanias8 shared
- Dane M Chetkovich5 shared
- Derek Alan Wainwright5 shared
- Richard J Miller3 shared
- H. Daniel Lacorazza2 shared
- Karl A Scheidt2 shared
- Jindan Yu2 shared
Most similar at Northwestern University
Same institution · by research overlap
- John F Disterhoft$28,289,467
- Deyu Fang$18,368,021
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingBindingPathway InteractionsPropertyIn VivoIn VitroMolecularExperimental StudyPlayNovel Therapeutic InterventionProteinsPharmaceutical PreparationsCellsMouse ModelPharmaceutical ChemistryToxic EffectBaseLeadResponseMalignant NeoplasmsPharmacologyComplexFutureSeries
Grant awards (22)
A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia$652,805
R01 · FY2025 · CA
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer$643,148
R01 · FY2025 · CA
IDO1 and Immunotolerance in Glioblastoma$502,054
R01 · FY2025 · NS
A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia$667,807
R01 · FY2024 · CA
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer$663,713
R01 · FY2024 · CA
IDO1 and Immunotolerance in Glioblastoma$487,318
R01 · FY2024 · NS
Development of in vivo probes to study the function of TRIP8b in cognition$825,034
R56 · FY2023 · MH
IDO1 and Immunotolerance in Glioblastoma$515,890
R01 · FY2023 · NS
Development of Novel MNK Inhibitors for Treating Glioblastoma$501,170
R01 · FY2023 · NS
Development of in vivo probes to study the function of TRIP8b in cognition$847,526
R56 · FY2022 · MH
IDO1 and Immunotolerance in Glioblastoma$628,320
R01 · FY2022 · NS
Development of Novel MNK Inhibitors for Treating Glioblastoma$501,170
R01 · FY2022 · NS
IDO1 and Immunotolerance in Glioblastoma$627,010
R01 · FY2021 · NS
Development of Novel MNK Inhibitors for Treating Glioblastoma$501,170
R01 · FY2021 · NS
Development of Novel MNK Inhibitors for Treating Glioblastoma$501,170
R01 · FY2020 · NS
Development of Novel MNK Inhibitors for Treating Glioblastoma$507,687
R01 · FY2019 · NS
Discovery of novel small molecule antidepressants$330,894
R01 · FY2018 · MH
Small molecule CXCR4 modulators as molecular probes for studying AML$513,581
R01 · FY2017 · CA · contact PI
Discovery of novel small molecule antidepressants$386,250
R01 · FY2017 · MH
Small molecule CXCR4 modulators as molecular probes for studying AML$539,886
R01 · FY2016 · CA · contact PI
Discovery of novel small molecule antidepressants$386,250
R01 · FY2016 · MH
Small molecule CXCR4 modulators as molecular probes for studying AML$529,121
R01 · FY2015 · CA · contact PI